Literature DB >> 16889436

JNK1 as a molecular target to limit cellular mortality under hypoxia.

Seema Betigeri1, Refika I Pakunlu, Yang Wang, Jayant J Khandare, Tamara Minko.   

Abstract

Many pathological conditions and environmental impacts lead to a decrease in tissue oxygen supply and severe cellular hypoxia. This secondary hypoxia can disturb cellular homeostasis, limiting the efficacy of the prescribed treatment for the primary lesion, eventually leading to cellular and organismal death. Jun N-terminal kinase 1 (JNK1) plays a major role in the hypoxic cellular damage. Therefore, we hypothesized that suppression of JNK1 activity will decrease cellular mortality under hypoxia and might increase the efficacy of traditional treatment of many pathological conditions. These investigations are aimed at studying the influence of the suppression of JNK1 activity on the development of cellular hypoxic damage. We used antisense oligonucleotides (ASO) and small interfering RNA (siRNA) targeted to JNK1 mRNA to inhibit the protein synthesis. Experiments were carried out on a cell culture under normoxia and hypoxic conditions that led to the death of approximately 50% of cells. ASO or siRNA was delivered by neutral or cationic liposomes. Intracellular localization of ASO and liposomes and mechanisms of apoptosis were studied. We found that the suppression of JNK1 activity by liposomal antisense oligonucleotides or siRNA limits the caspase-dependent apoptosis signaling pathway and decreases cellular mortality after severe hypoxia. JNK1 protein might be an attractive target for antihypoxic therapy in increasing resistance to many pathological conditions and diseases, leading to the oxygen deficit.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16889436     DOI: 10.1021/mp060014x

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  8 in total

1.  Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery.

Authors:  Oleh Taratula; Olga B Garbuzenko; Paul Kirkpatrick; Ipsit Pandya; Ronak Savla; Vitaly P Pozharov; Huixin He; Tamara Minko
Journal:  J Control Release       Date:  2009-06-28       Impact factor: 9.776

2.  Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug.

Authors:  Olga B Garbuzenko; Maha Saad; Seema Betigeri; Min Zhang; Alexandre A Vetcher; Viatcheslav A Soldatenkov; David C Reimer; Vitaly P Pozharov; Tamara Minko
Journal:  Pharm Res       Date:  2008-10-29       Impact factor: 4.200

3.  Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug.

Authors:  Vatsal Shah; Oleh Taratula; Olga B Garbuzenko; Olena R Taratula; Lorna Rodriguez-Rodriguez; Tamara Minko
Journal:  Clin Cancer Res       Date:  2013-09-13       Impact factor: 12.531

4.  Internally cationic polyamidoamine PAMAM-OH dendrimers for siRNA delivery: effect of the degree of quaternization and cancer targeting.

Authors:  Mahesh L Patil; Min Zhang; Oleh Taratula; Olga B Garbuzenko; Huixin He; Tamara Minko
Journal:  Biomacromolecules       Date:  2009-02-09       Impact factor: 6.988

5.  Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer.

Authors:  Maha Saad; Olga B Garbuzenko; Tamara Minko
Journal:  Nanomedicine (Lond)       Date:  2008-12       Impact factor: 5.307

6.  Multifunctional triblock Nanocarrier (PAMAM-PEG-PLL) for the efficient intracellular siRNA delivery and gene silencing.

Authors:  Mahesh L Patil; Min Zhang; Tamara Minko
Journal:  ACS Nano       Date:  2011-02-15       Impact factor: 15.881

7.  Non-viral systemic delivery of siRNA or antisense oligonucleotides targeted to Jun N-terminal kinase 1 prevents cellular hypoxic damage.

Authors:  Seema Betigeri; Min Zhang; Olga Garbuzenko; Tamara Minko
Journal:  Drug Deliv Transl Res       Date:  2010-12-14       Impact factor: 4.617

8.  Selective inhibition of JNK located on mitochondria protects against mitochondrial dysfunction and cell death caused by endoplasmic reticulum stress in mice with LPS‑induced ALI/ARDS.

Authors:  Congcong Li; Debin Ma; Yan Chen; Wei Liu; Faguang Jin; Liyan Bo
Journal:  Int J Mol Med       Date:  2022-05-06       Impact factor: 5.314

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.